Project Grant R01CA300144
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $499K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Jacksonville, FL 32224, USA
Similar Awards
- Federal Grant Award Summary Mayo Clinic Arizona has been awarded $156,080 by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) to conduct research on the functional role of KLRG1+ conventional helper T cells in the tumor microenvironment. The project, which commenced on December 25, 2025, and will conclude on July 31, 2028, aims to define how killer cell lectin-like receptor G1 (KLRG1) expressing CD4+ T cells contribute to cancer progression and immune...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1,098,920 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 13, 2025, with completion targeted for April 30, 2030. The research focuses on understanding the transcriptional and epigenetic control of CD8+ tumor-infiltrating lymphocytes (TILs) and tumor memory cells to enhance anti-tumor immune responses....
- Federal Project Grant Award Summary Mayo Clinic Arizona received a $657,698 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded on June 1, 2026, with a project completion date of May 31, 2031. This five-year research initiative investigates the molecular mechanisms by which TRPS1 (Transcriptional Repressor GATA Binding 1) regulates regulatory T cell (Treg) phenotype, function, and lineage stability in tumor microenvironments. The...
- Federal Grant Award Summary The National Cancer Institute awarded Mayo Clinic a $659,028 Research Project Grant (R01) under the Cancer Treatment Research program (CFDA 93.395) on May 20, 2026, with a completion date of April 30, 2031. This research initiative focuses on developing novel multi-modality treatment combinations to improve therapeutic outcomes for high-risk Ewing sarcoma patients, specifically those with STAG2 (Stromal Antigen 2) loss who experience significantly worse prognoses. The...
- Federal Grant Award Summary Mayo Clinic received a $2.46 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2029. The grant funds research and development of NKG7-armed tumor-infiltrating lymphocyte (TIL) therapy for metastatic uveal melanoma treatment. This immunotherapy research initiative represents the DHA's investment in advanced biomedical research...
- Federal Grant Award Summary Mayo Clinic received a $484,803 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 18, 2025, with completion scheduled for July 31, 2030. This research initiative focuses on elucidating glioma risk and improving patient outcomes by integrating germline and somatic genetics analysis. The project addresses critical gaps in understanding the functional relevance of 30 known germline...
- Federal Project Grant Award Summary Mayo Clinic received a $558,016 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded May 8, 2026, with completion targeted for April 30, 2031. The project investigates accelerated biological aging and immunosenescence as drivers of racial disparities in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma (MM). The research aims to understand why African American...
- Federal Project Grant Award Summary Mayo Clinic received a $100,228 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2026, with completion targeted for May 5, 2029. This award supports biomedical research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The grant funds research activities conducted at Mayo Clinic's Rochester, Minnesota facility,...
- Federal Project Grant Award Summary New York University School of Medicine received a $695,852 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on May 1, 2026, with a completion date of April 30, 2031. The award funds fundamental research investigating T cell circuits in the lymphatic system during melanoma progression, specifically examining tumor-draining lymph nodes (TDLNs) as key immune surveillance hubs. The research...
- Federal Grant Award Summary Mayo Clinic received a $667,710 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective March 20, 2026 through February 28, 2031. This award supports a randomized Phase 2 clinical trial designed to refine personalized treatment strategies for patients with oligometastatic castration-sensitive prostate cancer (OMCSPC) by integrating blood-based biomarkers with stereotactic body radiation therapy...